TP53 and non-small cell lung carcinoma: Three potential genetic subtypes identified in the “real-world” study showed that the cohort without TP53/RB1 alteration may benefit from targeting the virus or regaining the function of TP53; the cohort with STK11 mutation may exclude the efficacy of ICIs, and the cohort transformed from NSCLC with typical oncogenic driver mutations may avoid transformation with better treatment [62].